Program cost analysis of influenza vaccination of health care workers in Albania.
Cost analysis
Economic evaluation
Health care workers
Influenza
Low- and middle-income countries
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
10 01 2020
10 01 2020
Historique:
received:
16
08
2019
revised:
01
10
2019
accepted:
09
10
2019
pubmed:
2
11
2019
medline:
10
2
2021
entrez:
1
11
2019
Statut:
ppublish
Résumé
Since 2012, WHO has recommended influenza vaccination for health care workers (HCWs), which has different costs than routine infant immunization; however, few cost estimates exist from low- and middle-income countries. Albania, a middle-income country, has self-procured influenza vaccine for some HCWs since 2014, supplemented by vaccine donations since 2016 through the Partnership for Influenza Vaccine Introduction (PIVI). We conducted a cost analysis of HCW influenza vaccination in Albania to inform scale-up and sustainability decisions. We used the WHO's Seasonal Influenza Immunization Costing Tool (SIICT) micro-costing approach to estimate incremental costs from the government perspective of facility-based vaccination of HCWs in Albania with trivalent inactivated influenza vaccine for the 2018-19 season based on 2016-17 season data from administrative records, key informant consultations, and a convenience sample of site visits. Scenario analyses varied coverage, vaccine presentation, and vaccine prices. In the baseline scenario, 13,377 HCWs (70% of eligible HCWs) would be vaccinated at an incremental financial cost of US$61,296 and economic cost of US$161,639. Vaccine and vaccination supplies represented the largest share of financial (89%) and economic costs (44%). Per vaccinated HCW financial cost was US$4.58 and economic cost was US$12.08 including vaccine and vaccination supplies (US$0.49 and US$6.76 respectively without vaccine and vaccination supplies). Scenarios with higher coverage, pre-filled syringes, and higher vaccine prices increased total economic and financial costs, although the economic cost per HCW vaccinated decreased with higher coverage as some costs were spread over more HCWs. Across all scenarios, economic costs were <0.07% of Albania's estimated government health expenditure, and <5.07% of Albania's estimated immunization program economic costs. Cost estimates can help inform decisions about scaling up influenza vaccination for HCWs and other risk groups.
Sections du résumé
BACKGROUND
Since 2012, WHO has recommended influenza vaccination for health care workers (HCWs), which has different costs than routine infant immunization; however, few cost estimates exist from low- and middle-income countries. Albania, a middle-income country, has self-procured influenza vaccine for some HCWs since 2014, supplemented by vaccine donations since 2016 through the Partnership for Influenza Vaccine Introduction (PIVI). We conducted a cost analysis of HCW influenza vaccination in Albania to inform scale-up and sustainability decisions.
METHODS
We used the WHO's Seasonal Influenza Immunization Costing Tool (SIICT) micro-costing approach to estimate incremental costs from the government perspective of facility-based vaccination of HCWs in Albania with trivalent inactivated influenza vaccine for the 2018-19 season based on 2016-17 season data from administrative records, key informant consultations, and a convenience sample of site visits. Scenario analyses varied coverage, vaccine presentation, and vaccine prices.
RESULTS
In the baseline scenario, 13,377 HCWs (70% of eligible HCWs) would be vaccinated at an incremental financial cost of US$61,296 and economic cost of US$161,639. Vaccine and vaccination supplies represented the largest share of financial (89%) and economic costs (44%). Per vaccinated HCW financial cost was US$4.58 and economic cost was US$12.08 including vaccine and vaccination supplies (US$0.49 and US$6.76 respectively without vaccine and vaccination supplies). Scenarios with higher coverage, pre-filled syringes, and higher vaccine prices increased total economic and financial costs, although the economic cost per HCW vaccinated decreased with higher coverage as some costs were spread over more HCWs. Across all scenarios, economic costs were <0.07% of Albania's estimated government health expenditure, and <5.07% of Albania's estimated immunization program economic costs.
CONCLUSIONS
Cost estimates can help inform decisions about scaling up influenza vaccination for HCWs and other risk groups.
Identifiants
pubmed: 31669063
pii: S0264-410X(19)31400-8
doi: 10.1016/j.vaccine.2019.10.027
pmc: PMC10621071
mid: NIHMS1914928
pii:
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
220-227Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Informations de copyright
Published by Elsevier Ltd.
Références
Health Policy Plan. 2016 Nov;31(9):1225-31
pubmed: 27175031
Wkly Epidemiol Rec. 2012 May 25;87(21):201-16
pubmed: 24340402
Vaccine. 2015 Nov 27;33(48):6537-44
pubmed: 26597032
J Infect Dis. 2011 Jul;204 Suppl 1:S82-9
pubmed: 21666218
PLoS One. 2017 Aug 24;12(8):e0183391
pubmed: 28837594
Trop Med Int Health. 2008 Dec;13(12):1430-2
pubmed: 18983273
Vaccine. 2017 Oct 13;35(43):5734-5737
pubmed: 28893473
Rev Salud Publica (Bogota). 2008 Nov-Dec;10(5):756-66
pubmed: 19360224
PLoS One. 2018 Jun 7;13(6):e0198685
pubmed: 29879206
Vaccine. 2018 Feb 8;36(7):997-1007
pubmed: 29373192
Vaccine. 2013 Nov 4;31(46):5339-48
pubmed: 24055351
PLoS One. 2017 Feb 7;12(2):e0171499
pubmed: 28170416
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
PLoS One. 2017 Dec 27;12(12):e0190006
pubmed: 29281710
Hum Vaccin Immunother. 2013 Jul;9(7):1500-11
pubmed: 23732900
Influenza Other Respir Viruses. 2018 Mar;12(2):211-219
pubmed: 29024434